Nontuberculous Mycobacteria (NTM) Infections - Pipeline Insight, 2021
This report can be delivered to the clients within 48 hours
DelveInsight’s, “Nontuberculous Mycobacteria (NTM) Infections - Pipeline Insight, 2021,” report provides comprehensive insights about 14+ companies and 14+ pipeline drugs in Nontuberculous Mycobacteria (NTM) Infections pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
Nontuberculous Mycobacteria (NTM) Infections: Overview
Non-tuberculous mycobacteria (NTM) are ubiquitous, free living, environmental saprophytic organisms known to occupy water systems, soil, and vegetation. Infections caused by NTM is known as Nontuberculous Mycobacteria (NTM) Infections. NTM disease presents a wide variety of clinical syndromes, from lymphadenopathy (commonly cervical lymph nodes) to aseptic meningitis. Diagnosis of nontuberculous mycobacterial (NTM) lung disease include chest radiograph, three or more sputum specimens for acid-fast bacilli (AFB) analysis and exclusion of other disorders, such as tuberculosis (TB). Clinical, radiographic, and microbiologic criteria are equally important and all must be met to make a diagnosis of NTM lung disease. Treatment for NTM infections generally prolonged (12–18 months) multi-drug therapy. Disease remission rates vary depending on infecting species, patient age and comorbidities.
'Nontuberculous Mycobacteria (NTM) Infections - Pipeline Insight, 2021' report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Nontuberculous Mycobacteria (NTM) Infections pipeline landscape is provided which includes the disease overview and Nontuberculous Mycobacteria (NTM) Infections treatment guidelines. The assessment part of the report embraces, in depth Nontuberculous Mycobacteria (NTM) Infections commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Nontuberculous Mycobacteria (NTM) Infections collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
This segment of the Nontuberculous Mycobacteria (NTM) Infections report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Nontuberculous Mycobacteria (NTM) Infections Emerging Drugs
Further product details are provided in the report
Nontuberculous Mycobacteria (NTM) Infections: Therapeutic Assessment
This segment of the report provides insights about the different Nontuberculous Mycobacteria (NTM) Infections drugs segregated based on following parameters that define the scope of the report, such as:
Nontuberculous Mycobacteria (NTM) Infections: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses Nontuberculous Mycobacteria (NTM) Infections therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Nontuberculous Mycobacteria (NTM) Infections drugs.
Nontuberculous Mycobacteria (NTM) Infections Report Insights
Current Treatment Scenario and Emerging Therapies:
DelveInsight’s, “Nontuberculous Mycobacteria (NTM) Infections - Pipeline Insight, 2021,” report provides comprehensive insights about 14+ companies and 14+ pipeline drugs in Nontuberculous Mycobacteria (NTM) Infections pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
- Global coverage
Nontuberculous Mycobacteria (NTM) Infections: Overview
Non-tuberculous mycobacteria (NTM) are ubiquitous, free living, environmental saprophytic organisms known to occupy water systems, soil, and vegetation. Infections caused by NTM is known as Nontuberculous Mycobacteria (NTM) Infections. NTM disease presents a wide variety of clinical syndromes, from lymphadenopathy (commonly cervical lymph nodes) to aseptic meningitis. Diagnosis of nontuberculous mycobacterial (NTM) lung disease include chest radiograph, three or more sputum specimens for acid-fast bacilli (AFB) analysis and exclusion of other disorders, such as tuberculosis (TB). Clinical, radiographic, and microbiologic criteria are equally important and all must be met to make a diagnosis of NTM lung disease. Treatment for NTM infections generally prolonged (12–18 months) multi-drug therapy. Disease remission rates vary depending on infecting species, patient age and comorbidities.
'Nontuberculous Mycobacteria (NTM) Infections - Pipeline Insight, 2021' report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Nontuberculous Mycobacteria (NTM) Infections pipeline landscape is provided which includes the disease overview and Nontuberculous Mycobacteria (NTM) Infections treatment guidelines. The assessment part of the report embraces, in depth Nontuberculous Mycobacteria (NTM) Infections commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Nontuberculous Mycobacteria (NTM) Infections collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
- The companies and academics are working to assess challenges and seek opportunities that could influence Nontuberculous Mycobacteria (NTM) Infections R&D. The therapies under development are focused on novel approaches to treat/improve Nontuberculous Mycobacteria (NTM) Infections.
This segment of the Nontuberculous Mycobacteria (NTM) Infections report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Nontuberculous Mycobacteria (NTM) Infections Emerging Drugs
- RHB 204: RedHill Biopharma
- MAT2501: Matinas BioPharma
Further product details are provided in the report
Nontuberculous Mycobacteria (NTM) Infections: Therapeutic Assessment
This segment of the report provides insights about the different Nontuberculous Mycobacteria (NTM) Infections drugs segregated based on following parameters that define the scope of the report, such as:
- Major Players in Nontuberculous Mycobacteria (NTM) Infections
- Phases
- Late stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
- Oral
- Parenteral
- Intravitreal
- Subretinal
- Topical
- Molecule Type
- Monoclonal Antibody
- Peptides
- Polymer
- Small molecule
- Gene therapy
- Product Type
Nontuberculous Mycobacteria (NTM) Infections: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses Nontuberculous Mycobacteria (NTM) Infections therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Nontuberculous Mycobacteria (NTM) Infections drugs.
Nontuberculous Mycobacteria (NTM) Infections Report Insights
- Nontuberculous Mycobacteria (NTM) Infections Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Treatment Scenario and Emerging Therapies:
- How many companies are developing Nontuberculous Mycobacteria (NTM) Infections drugs?
- How many Nontuberculous Mycobacteria (NTM) Infections drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Nontuberculous Mycobacteria (NTM) Infections?
- What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Nontuberculous Mycobacteria (NTM) Infections therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Nontuberculous Mycobacteria (NTM) Infections and their status?
- What are the key designations that have been granted to the emerging drugs?
- RedHill Biopharma
- Janssen Pharmaceutical
- Spero Therapeutics
- Revimmune
- Matinas BioPharma
- MannKind Corporation
- Spero Therapeutics
- Shionogi
- Crestone
- RHB 204
- Bedaquiline
- SPR 720
- CYT107
- MAT2501
- MNKD-10
- SPR-719
- Research programme: mycobacterial disease therapeutics
- MmpL3 inhibitor
Introduction
Executive Summary
Nontuberculous Mycobacteria (NTM) Infections: Overview
Causes
Mechanism of Action
Signs and Symptoms
Diagnosis
Disease Management
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Nontuberculous Mycobacteria (NTM) Infections – DelveInsight’s Analytical Perspective
In-depth Commercial Assessment
Nontuberculous Mycobacteria (NTM) Infections companies’ collaborations, Licensing, Acquisition -Deal Value Trends
Nontuberculous Mycobacteria (NTM) Infections Collaboration Deals
Company-Company Collaborations (Licensing / Partnering) Analysis
Company-University Collaborations (Licensing / Partnering) Analysis
Late Stage Products (Phase III)
Comparative Analysis
RHB 204: RedHill Biopharma
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report
Mid Stage Products (Phase II)
Comparative Analysis
CYT107: Revimmune
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report
Early Stage Products (Phase I)
Comparative Analysis
MAT2501: Matinas BioPharma
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report
Preclinical and Discovery Stage Products
Comparative Analysis
MNKD-10: MannKind Corporation
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report
Inactive Products
Comparative Analysis
Nontuberculous Mycobacteria (NTM) Infections Key Companies
Nontuberculous Mycobacteria (NTM) Infections Key Products
Nontuberculous Mycobacteria (NTM) Infections- Unmet Needs
Nontuberculous Mycobacteria (NTM) Infections- Market Drivers and Barriers
Nontuberculous Mycobacteria (NTM) Infections- Future Perspectives and Conclusion
Nontuberculous Mycobacteria (NTM) Infections Analyst Views
Nontuberculous Mycobacteria (NTM) Infections Key Companies
Appendix
Executive Summary
Nontuberculous Mycobacteria (NTM) Infections: Overview
Causes
Mechanism of Action
Signs and Symptoms
Diagnosis
Disease Management
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Nontuberculous Mycobacteria (NTM) Infections – DelveInsight’s Analytical Perspective
In-depth Commercial Assessment
Nontuberculous Mycobacteria (NTM) Infections companies’ collaborations, Licensing, Acquisition -Deal Value Trends
Nontuberculous Mycobacteria (NTM) Infections Collaboration Deals
Company-Company Collaborations (Licensing / Partnering) Analysis
Company-University Collaborations (Licensing / Partnering) Analysis
Late Stage Products (Phase III)
Comparative Analysis
RHB 204: RedHill Biopharma
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report
Mid Stage Products (Phase II)
Comparative Analysis
CYT107: Revimmune
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report
Early Stage Products (Phase I)
Comparative Analysis
MAT2501: Matinas BioPharma
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report
Preclinical and Discovery Stage Products
Comparative Analysis
MNKD-10: MannKind Corporation
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report
Inactive Products
Comparative Analysis
Nontuberculous Mycobacteria (NTM) Infections Key Companies
Nontuberculous Mycobacteria (NTM) Infections Key Products
Nontuberculous Mycobacteria (NTM) Infections- Unmet Needs
Nontuberculous Mycobacteria (NTM) Infections- Market Drivers and Barriers
Nontuberculous Mycobacteria (NTM) Infections- Future Perspectives and Conclusion
Nontuberculous Mycobacteria (NTM) Infections Analyst Views
Nontuberculous Mycobacteria (NTM) Infections Key Companies
Appendix
LIST OF TABLES
Table 1 Total Products for Nontuberculous Mycobacteria (NTM) Infections
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
Table 1 Total Products for Nontuberculous Mycobacteria (NTM) Infections
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
LIST OF FIGURES
Figure 1 Total Products for Nontuberculous Mycobacteria (NTM) Infections
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
Figure 1 Total Products for Nontuberculous Mycobacteria (NTM) Infections
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products